Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Rectal cancer Indication Strategy Report 2026: EGFR, Trials and Deals
24 July 2026
2026 Rectal cancer strategy: epidemiology, EGFR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Latest Hotspot
8 min read
Microsatellite instability-high colorectal cancer Indication Strategy Report 2026: PD-1, Trials and Deals
24 July 2026
2026 Microsatellite instability-high colorectal cancer strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market…
Read →
Latest Hotspot
8 min read
EBV-positive gastric cancer Indication Strategy Report 2026: PD-1, Trials and Deals
24 July 2026
2026 EBV-positive gastric cancer strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Latest Hotspot
8 min read
Diffuse gastric cancer Indication Strategy Report 2026: CDH1, Trials and Deals
24 July 2026
2026 Diffuse gastric cancer strategy: epidemiology, CDH1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Latest Hotspot
8 min read
Gastric signet ring cell carcinoma Indication Strategy Report 2026: CLDN18.2, Trials and Deals
24 July 2026
2026 Gastric signet ring cell carcinoma strategy: epidemiology, CLDN18.2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Latest Hotspot
8 min read
Vulvodynia Indication Strategy Report 2026: TRPV1, Trials and Deals
24 July 2026
2026 Vulvodynia strategy: epidemiology, TRPV1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Latest Hotspot
8 min read
Postpartum hemorrhage Indication Strategy Report 2026: Oxytocin receptor, Trials and Deals
24 July 2026
2026 Postpartum hemorrhage strategy: epidemiology, Oxytocin receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Latest Hotspot
8 min read
Endometrial hyperplasia Indication Strategy Report 2026: Progesterone receptor, Trials and Deals
24 July 2026
2026 Endometrial hyperplasia strategy: epidemiology, Progesterone receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Latest Hotspot
8 min read
Intrahepatic cholestasis of pregnancy Indication Strategy Report 2026: FXR, Trials and Deals
24 July 2026
2026 Intrahepatic cholestasis of pregnancy strategy: epidemiology, FXR biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Latest Hotspot
8 min read
Hyperemesis gravidarum Indication Strategy Report 2026: GDF15, Trials and Deals
24 July 2026
2026 Hyperemesis gravidarum strategy: epidemiology, GDF15 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Latest Hotspot
8 min read
Placenta accreta spectrum Indication Strategy Report 2026: VEGF, Trials and Deals
24 July 2026
2026 Placenta accreta spectrum strategy: epidemiology, VEGF biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Latest Hotspot
8 min read
Kallmann syndrome Indication Strategy Report 2026: GnRH receptor, Trials and Deals
24 July 2026
2026 Kallmann syndrome strategy: epidemiology, GnRH receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
<
1
<<
1158
1159
1160
1161
1162
>>
2218
>